Topline data expected by year end Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure ...

ATLANTA, May 29, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of ...

Alzamend’s recently completed Phase IIA study of AL001 in Alzheimer’s patients and healthy subjects showed a benign safety profile and identified a candidate dose that is unlikely to require ...

ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for ...

The MarketWatch News Department was not involved in the creation of this content. -- Topline data expected by year end -- Head-to-head studies of AL001 versus a marketed lithium carbonate product will ...

A wearable sensor could vastly improve treatment and drug safety for millions of patients who take lithium for bipolar disorder. Lithium is a highly effective treatment for bipolar disorder, but the ...

Although lithium is highly effective in treating bipolar disorder, the chemical has a narrow therapeutic window—too high a dose can be toxic to patients, causing kidney damage, thyroid damage, or even ...

When someone mentions the word “toxicity” in relation to cancer treatment, they’re usually referring to the negative physical side effects and complications that can result from therapies like ...